“It’s a Way of Reparations”: Why Henrietta Lacks Settlement Matters for Bioethics & Racial Justice
By Amy Goodman,
Democracy Now!
| 08. 07. 2023
The family of Henrietta Lacks, a Black cancer patient whose cells were taken by Johns Hopkins University Hospital without her consent in 1951, has reached a deal over the unethical use of her cells with pharmaceutical company Thermo Fisher Scientific. Henrietta Lacks’s family has denounced the racist medical system that allowed the biotech company to make billions in profit from the “HeLa” cell line, which helped produce remedies for multiple diseases, including the first polio vaccine. Details of the settlement were not made public, but the plaintiffs celebrated the lawsuit’s resolution last Tuesday, on Henrietta Lack’s birthday. For more on the case and the history of medical racism in the United States, we speak with Dorothy Roberts, director of the University of Pennsylvania Program on Race, Science and Society. She is the author of several books, including Fatal Invention: How Science, Politics, and Big Business Re-create Race in the Twenty-first Century. “What happened to Henrietta Lacks didn’t just happen to her. It’s part of a long history of experimentation and exploitation of Black people in biomedical research,” says Roberts...
Related Articles
By Tomoko Otake, The Japan Times | 04.09.2024
A decade ago, researcher Haruko Obokata caused a sensation when she published two papers in the journal Nature, in which she claimed that she had discovered a way to create stem cells easily using the so-called STAP method.
With STAP...
By Ian Sample, The Guardian | 03.08.2024
Scientists are a step closer to making IVF eggs from patients’ skin cells after adapting the procedure that created Dolly the sheep, the first cloned mammal, more than two decades ago.
The work raises the prospect of older women being...
By Ramon Antonio Vargas, The Guardian | 02.28.2024
Doctors say a man in California who contracted blood cancer while living with HIV is in remission from both potentially fatal illnesses thanks to a treatment they are hailing as remarkable and encouraging.
Paul Edmonds is only the fifth-known person...
By Victoria Gray, Uduak Thomas, and Kevin Davies, The CRISPR Journal | 02.14.2024
In July 2019, medical staff in Nashville dosed the first U.S. patient in the exa-cel therapy trial, sponsored by Vertex Pharmaceuticals and CRISPR Therapeutics. That first patient was Victoria Gray, a mother of four from Forest, Mississippi, a sickle cell...